#### ENDO PHARMA LLC

Form 4

December 22, 2005

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

**OMB APPROVAL** 

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \*

2. Issuer Name and Ticker or Trading

Issuer

**ENDO PHARMA LLC** 

**ENDO PHARMACEUTICALS** HOLDINGS INC [ENDP]

(Check all applicable)

5. Relationship of Reporting Person(s) to

(Last) (First) (Middle) 3. Date of Earliest Transaction

(7:-

(Month/Day/Year)

\_X\_\_ 10% Owner Director \_\_ Other (specify Officer (give title below)

320 PARK AVENUE 12/13/2005

> (Street) 4. If Amendment, Date Original

Symbol

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

NEW YORK, NY 10022

(Ctata)

(City)

(City)	(State) (Z	Zip) Table	e I - Non-D	erivative S	Securit	ties Acq	uired, Disposed o	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired tion(A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Form: Direct Beneficially (D) or Owned Indirect (I) Following (Instr. 4) Reported		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock, par value \$.01 per share	12/13/2005		X	10,340	` ´	\$ 2.42	20,361,695	D	
Common Stock, par value \$.01 per share	12/13/2005		X	2,997	D	\$ 2.42	20,358,698	D	
Common Stock, par value \$.01 per share	12/13/2005		X	1,577	D	\$ 2.42	20,357,121	D	

### Edgar Filing: ENDO PHARMA LLC - Form 4

Common Stock, par value \$.01 per share	12/13/2005	X	18,313	D	\$ 3	20,338,808	D
Common Stock, par value \$.01 per share	12/13/2005	X	3,308	D	\$ 3	20,335,500	D
Common Stock, par value \$.01 per share	12/13/2005	X	1,356	D	\$ 3.42	20,334,144	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun or Numbe of Shar
Call Option (obligation to sell)	\$ 2.42	12/13/2005		X		10,340	10/13/2005	08/26/2007	Common Stock	10,34
Call Option (obligation to sell)	\$ 2.42	12/13/2005		X		2,997	10/13/2005	08/26/2007	Common Stock	2,997
Call Option (obligation to sell)	\$ 2.42	12/13/2005		X		1,577	10/13/2005	08/26/2007	Common Stock	1,577
Call Option (obligation to sell)	\$ 3	12/13/2005		X		18,313	10/13/2005	08/26/2007	Common Stock	18,31
Call Option (obligation	\$ 3	12/13/2005		X		3,308	10/13/2005	08/26/2007	Common Stock	3,308

to sell)

Call Option

Common 12/13/2005 1,356 10/13/2005 08/26/2007 (obligation \$ 3.42 X Stock

1,356

to sell)

# **Reporting Owners**

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

> > X

ENDO PHARMA LLC 320 PARK AVENUE NEW YORK, NY 10022

**Signatures** 

/s/ Jeffrey R. Black Chief Financial 12/22/2005 Officer

> \*\*Signature of Reporting Person Date

## **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3

Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).